ACE2 and COVID-19: Clinically, this RAAS imbalance correlates with severe COVID-19 outcomes, indicating that while ACE2 downregulation may limit viral entry, it risks exacerbating disease by disrupting homeostatic pathways (Wang X et al., 2025).